A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial
Rachel Galot, Christophe Le Tourneau, Esma Saâda-Bouzid, Amaury Daste, Caroline Even, Philip R. Debruyne, Stéphanie Henry, Sylvie Zanetta, A. Rutten, Lisa Licitra, Jean‐Luc Canon, Marie‐Christine Kaminsky, Pol Specenier, Sylvie Rottey, J. Guigay, Anthony Kong, Inge Tinhofer, Édith Borcoman, L. Dirix, Tiana Raveloarivahy, Catherine Fortpied, Maureen Vanlancker, Marie Morfouace, Anne-Sophie Govaerts, Jean‐Pascal Machiels
Topics & Concepts
MedicineInternal medicineImmunotherapyOncologyHead and neck squamous-cell carcinomaResponse Evaluation Criteria in Solid TumorsCohortAdverse effectHead and neck cancerPhases of clinical researchGastroenterologyCancerClinical trialImmune Cell Function and InteractionCancer Immunotherapy and BiomarkersHead and Neck Cancer Studies